The evolving field of cardio-oncology: beyond anthracyclines and heart failure.
Division of Cardiovascular Medicine, University of South Florida, Tampa, FL, USA; and Cardio-Oncology ProgramH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA mfradley@health.usf.edu.
Michael G
MG
Fradley
D018943:Anthracyclines / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D066126:Cardiotoxicity / Q000209:etiology*; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D056747:Immunomodulation; D009369:Neoplasms / Q000209:etiology / Q000628:therapy*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
D018943:Anthracyclines; D000970:Antineoplastic Agents; D011505:Protein-Tyrosine Kinases